Ken Aoshima

Q: What is Ken Aoshima email address?

Email Ken Aoshima at kenaoshima@gmail.com and ken_aoshima@eisai.com. This email is the most updated Ken Aoshima's email found in 2026.

Q: How to contact Ken Aoshima?

To contact Ken Aoshima send an email to kenaoshima@gmail.com or ken_aoshima@eisai.com. (updated on March 18, 2025)

Director at Eisai | Japan

About Ken Aoshima

Ken Aoshima, Senior Scientist at Eisai, brings a wealth of expertise in pre-clinical drug research and translational science, with a focus on advancing innovative therapeutic strategies. Currently, Ken plays a pivotal role in integrating cutting-edge bioinformatics and statistical modeling techniques into the company's clinical development pipeline. His leadership in establishing an in-house compounds database—now the sole global resource for Eisai—has significantly enhanced the company's ability to streamline drug discovery and optimize candidate selection. Additionally, Ken spearheaded the development of a comprehensive Proteomic/Metabolomics (OMICS) analysis platform, which incorporates novel quantitative algorithms for mass spectrometry-based research, enabling more precise biomarker discovery and mechanistic insights.

In his current role, Ken is instrumental in designing innovative clinical study protocols, leveraging his expertise in personalized medicine, machine learning, and electrophotography to develop robust statistical methods for clinical development plans. His work ensures high-quality analyses for Clinical Study Reports, NDA/BLA submissions, and regulatory authority consultations, emphasizing the importance of rigorous data integrity and interpretability. Moreover, Ken is actively involved in establishing biomarker analysis strategies within clinical trials, facilitating the identification of predictive and prognostic markers that can guide patient stratification and therapeutic decision-making.

Ken’s multidisciplinary skills—including SAS programming, PHP, and advanced statistical modeling—enable him to bridge the gap between pre-clinical research and clinical application effectively. His innovative approach, combined with a deep understanding of neurology and personalized medicine, positions him as a key contributor to Eisai’s mission to develop targeted, effective treatments for complex neurological disorders and beyond.

Ken Aoshima Work